1. Home
  2. IRD
  3. IRD News

Latest OPUS GENETICS INC (IRD) News on April 15, 2025

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
IRD

GlobeNewswire

7 days ago

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company’s Transformation and Progress
IRD

GlobeNewswire

8 days ago

Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company’s Transformation and Progress

Party Time: Brokers Just Made Major Increases To Their Opus Genetics, Inc. (NASDAQ:IRD) Earnings Forecasts
IRD

Simply Wall St.

10 days ago

Party Time: Brokers Just Made Major Increases To Their Opus Genetics, Inc. (NASDAQ:IRD) Earnings Forecasts

Opus Genetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
IRD

Simply Wall St.

11 days ago

Opus Genetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Opus Genetics to Participate in Upcoming Investor Conference in April
IRD

GlobeNewswire

13 days ago

Opus Genetics to Participate in Upcoming Investor Conference in April

Opus Genetics Announces Financial Results for Full Year 2024
IRD

GlobeNewswire

15 days ago

Opus Genetics Announces Financial Results for Full Year 2024

Several Insiders Invested In Opus Genetics Flagging Positive News
IRD

Simply Wall St.

20 days ago

Several Insiders Invested In Opus Genetics Flagging Positive News

IRD

GlobeNewswire

25 days ago

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX
IRD

GlobeNewswire

25 days ago

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
IRD

GlobeNewswire

25 days ago

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IRD

GlobeNewswire

a month ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
IRD

GlobeNewswire

a month ago

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs
IRD

GlobeNewswire

2 months ago

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
IRD

GlobeNewswire

2 months ago

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

IRD

GlobeNewswire

2 months ago

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

IRD

Argus Research

4 months ago

Daily – Vickers Top Buyers & Sellers for 12/31/2024

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
IRD

GlobeNewswire

4 months ago

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024
IRD

GlobeNewswire

4 months ago

Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

Opus Genetics reinstated with a Buy at H.C. Wainwright
IRD

TipRanks

5 months ago

Opus Genetics reinstated with a Buy at H.C. Wainwright

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IRD

GlobeNewswire

5 months ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
IRD

PR Newswire

6 months ago

The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics

Share on Social Networks: